T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Comfort Systems
FIX
$60.8B
| $22.6M | ﹤0.01% |
619,606
-2,478
| -0.4% | -$110K |
|
|
PCSB
1027
DELISTED
PCSB Financial Corporation
PCSB
| $22.6M | ﹤0.01% |
1,616,651
+66,802
| +4% | +$1.2M |
|
1028
EPAM Systems
EPAM
$5.24B
| $22.5M | ﹤0.01% |
121,339
-117,060
| -49% | -$25.3M |
|
1029
Arista Networks
ANET
$257B
| $22.5M | ﹤0.01% |
1,776,544
+145,488
| +9% | +$1.89M |
|
1030
A.O. Smith
AOS
$8.49B
| $22.5M | ﹤0.01% |
594,811
+3,781
| +0.6% | +$161K |
|
1031
Alector
ALEC
$228M
| $22.4M | ﹤0.01% |
+929,364
| New | +$23.7M |
|
1032
Merit Medical Systems
MMSI
$5.4B
| $22.3M | ﹤0.01% |
714,372
+677,012
| +1,812% | +$24.1M |
|
1033
CAE Inc. Common Shares
CAE
$8.47B
| $22.3M | ﹤0.01% |
1,785,751
-17,781
| -1% | -$449K |
|
1034
First Bancorp
FBNC
$2.74B
| $22.2M | ﹤0.01% |
963,598
-73,340
| -7% | -$2.4M |
|
|
BEAT
1035
DELISTED
BioTelemetry, Inc.
BEAT
| $22.2M | ﹤0.01% |
576,428
-2,466
| -0.4% | -$114K |
|
1036
Henry Schein
HSIC
$10B
| $22.2M | ﹤0.01% |
438,934
+17,488
| +4% | +$1.11M |
|
1037
Restaurant Brands International
QSR
$26.7B
| $22M | ﹤0.01% |
549,897
-13,382,082
| -96% | -$757M |
|
1038
Columbia Financial
CLBK
$1.22B
| $22M | ﹤0.01% |
1,526,922
+25,356
| +2% | +$406K |
|
1039
Hawkins
HWKN
$2.67B
| $21.9M | ﹤0.01% |
1,229,144
+17,786
| +1% | +$354K |
|
1040
NCR Voyix
VYX
$1.17B
| $21.8M | ﹤0.01% |
2,008,662
+32,323
| +2% | +$555K |
|
1041
W.W. Grainger
GWW
$62.2B
| $21.8M | ﹤0.01% |
87,578
+6,862
| +9% | +$2.03M |
|
1042
Silgan Holdings
SLGN
$4.46B
| $21.8M | ﹤0.01% |
749,815
+724,060
| +2,811% | +$21.8M |
|
1043
Quest Diagnostics
DGX
$26.1B
| $21.8M | ﹤0.01% |
270,867
+21,018
| +8% | +$2.18M |
|
|
AAT
1044
American Assets Trust
AAT
$1.41B
| $21.6M | ﹤0.01% |
863,599
+18,031
| +2% | +$729K |
|
|
SBT
1045
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $21.6M | ﹤0.01% |
5,020,308
+50,000
| +1% | +$325K |
|
1046
FMC
FMC
$1.27B
| $21.5M | ﹤0.01% |
263,393
+19,217
| +8% | +$1.78M |
|
1047
10x Genomics
TXG
$7.58B
| $21.5M | ﹤0.01% |
344,894
+160,810
| +87% | +$12.6M |
|
|
NVO
1048
Novo Nordisk
NVO
$205B
| $21.5M | ﹤0.01% |
+713,596
| New | +$21.2M |
|
|
EPZM
1049
DELISTED
Epizyme, Inc
EPZM
| $21.4M | ﹤0.01% |
1,382,150
-20,943
| -1% | -$450K |
|
1050
KeyCorp
KEY
$24.6B
| $21.4M | ﹤0.01% |
2,063,747
-160,338
| -7% | -$2.67M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.